GOODIX
27.2.2017 18:53:16 CET | Business Wire | Press release
Goodix (Shanghai Stock Exchange:603160), the premier developer of human interface and biometric solutions for mobile devices, announced today that Huawei P10 and P10 Plus, flagship smartphones of 2017 just launched at Mobile World Congress 2017, are using Invisible Fingerprint Sensor (IFS™) from Goodix.
Huawei’s P10 and P10 Plus smartphones have stylish, integrated screen panel design. The Home key has IFS™ embedded under the screen panel, allowing fingerprint authentication through the glass. IFS™ from Goodix enables the elegant and slim design of P10 and P10 Plus while providing secure and easy-to-use fingerprint authentication. This safeguards the smartphone and secures mobile transactions.
World’s first IFS™ solution meets Huawei’s design needs
Traditionally, a button needs to be placed on the front or at the back of a smartphone in order to install a fingerprint sensor. This means manufacturers need to open a hole on the glass panel for the button. This occupies space, affects the overall phone design and increases the complexity of manufacturing process. Goodix’s IFS™ addresses these issues by seamlessly integrating the sensor right under the glass panel without the need to drill a hole and place a button.
Goodix and Huawei share the same vision of innovating latest technologies to fulfill people’s desires and needs. The longstanding partnership between the two companies is a great success. Prior to the P10 and P10 Plus, a number of Huawei smartphones already use various Goodix’s fingerprint authentication and touchscreen controller solutions. The two companies will continue to innovate to provide safer, more convenient and intelligent technology to mobile users.
IFS™ gives manufacturers more flexibility to develop stylish, slim phone designs. It also supports thick glass panels and improves the water and dust resistance. All this combines to deliver a better user experience and higher reliability.
From R&D to successful commercialization
To authenticate fingerprints through glass panels poses many technical challenges and requires the redesign of circuits and the software algorithm. Goodix has been driving the development process from R&D to commercialization. Since IFS™ was launched in 2014, the company has worked closely with glass panel manufacturers and fingerprint module suppliers to ensure that the functionality, performance, reliability and supply of IFS can meet the various demands of mobile device manufacturers.
The successful commercialization of IFS™ reinforces Goodix as a global leader in biometric technology. This leading position is well recognized by global mobile brands. As of January 2017, Goodix has applied for and received more than 900 patents. The strong R&D capability propels Goodix forward to continue to innovate for mobile users. IFS™ won a Consumer Electronics Show (CES) Innovation Award in 2016, and Goodix was the first Chinese integrated circuit (IC) company to ever win this honor.
About Goodix:
Goodix , a premier developer and provider of fingerprint and touchscreen solutions for mobile phones, tablets and wearables, currently holds a diversified portfolio of fingerprint authentication solutions that provides excellent flexibility to suit the varying preferences from consumers and partners such as Live Finger Detection™, Invisible Fingerprint Sensor (IFS™), Glass-covered and Coating button sensors. In addition, Goodix has been actively involved in assisting Alipay and China UnionPay with reviewing industry standards for fingerprint authentication. An increasing number of top-tier handset manufacturers adopting fingerprints and touch solutions from the company. On October 17, 2016, Goodix was listed on the Shanghai Stock Exchange, the stock code is 603160.
Goodix™ and Invisible Fingerprint Sensor (IFS™) are trademarks of Goodix in China and other countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006232/en/
Contact:
FleishmanHillard, on behalf of Goodix
Alisa Davis, 415-318-4086
Alisa.davis@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom